No Data
No Data
Wedbush Assumes Coverage of Voyager With Outperform Rating
Bernstein Keeps Their Buy Rating on Novartis AG (NOVN)
Novartis (NVS.US) has received approval from the European Commission for its important small molecule drug, which is expected to transform the treatment of early-stage breast cancer.
Novartis will continue to evaluate the long-term outcomes of NATALEE patients, including overall survival.
European Commission Approves Products by BeiGene, GSK and Novartis
The European Commission Has Approved Novartis' Kisqali (Ribociclib) In Combination With An Aromatase Inhibitor For The Adjuvant Treatment Of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer At High Risk...
Novartis' Early Breast Cancer Drug Gets Approval From EU Commission
103827296 : Halo Medan hai hai English understand I'm sorry
72627089 : fractional shares
72627089 : would like to chat about fractional shares
(R-long)103834298 : stop all
l0lBElBgG : k